Baidu
map

Lancet:不容乐观——全球细菌抗生素耐药性引起的死亡事件远超想象!

2022-03-12 MedSci原创 MedSci原创

这项研究首次对全球细菌耐药性的负担进行了全面评估,并发现AMR是全世界的一个主要死因。

抗生素耐药性(AMR)对全世界的人类健康构成了重大威胁。此前有不少文献估计了AMR对特定地区特定病原体-药物组合的发病率、死亡、住院时间和医疗费用的影响,但都不够全面。

为此,来自国际抗生素耐药性联合工作组的专家开展了相关研究,评估了2019年204个国家和地区的23种病原体和88种病原体-药物组合可归因于细菌性AMR并与之相关的死亡和残疾调整寿命(DALYs),结果发表在Lancet杂志上。

研究人员系统性文献综述、医院系统、监测系统和其他来源获得数据,涵盖4.71亿份个人记录或分离物和7585个研究地点-年。使用预测性统计模型对所有地点的AMR负担进行了估计,包括没有数据的地点。利用这些成分,根据两个反事实估计了疾病负担:归因于AMR的死亡(基于所有耐药性感染被药物敏感性感染取代的另一种情况),以及与AMR有关的死亡(基于所有耐药性感染被无感染取代的另一种情况)。

根据预测性统计模型,2019年估计有4.95万(3.62-6.57)例与细菌性抗药性有关的死亡,包括1.27万(95% UI 0.91-1.71)例可归因于细菌性抗药性的死亡。在区域层面,可归因于耐药性的全年龄段死亡率在撒哈拉以南非洲西部最高,为27.3/10万人死亡,在大洋洲最低,为6.5/10万人。

下呼吸道感染占2019年与抵抗力有关的死亡人数超过150万,成为负担最重的传染病综合征。与耐药性有关的死亡的六种主要病原体(大肠杆菌,其次是金黄色葡萄球菌、肺炎克雷伯氏菌、肺炎链球菌、鲍曼不动杆菌和铜绿假单胞菌)在2019年造成929000例归因于AMR的死亡和357万例与AMR有关的死亡。

一种病原体-药物组合,即耐甲氧西林的金黄色葡萄球菌,在2019年造成了超过10万例归因于AMR的死亡,还有6种病原体分别造成了10万例以上的死亡:耐多药的不包括广泛耐药的结核病、第三代头孢菌的大肠杆菌、耐碳青霉烯的鲍曼纽氏菌、耐氟喹诺酮的大肠杆菌、耐碳青霉烯的K肺炎,以及第三代头孢菌的K肺炎。

综上,这项研究首次对全球细菌耐药性的负担进行了全面评估,并发现AMR是全世界的一个主要死因。

 

参考文献:

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. https://doi.org/10.1016/S0140-6736(21)02724-0

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1648816, encodeId=a1231648816a5, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Wed Nov 16 08:59:29 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831490, encodeId=6e411831490c2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 12 09:59:29 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441668, encodeId=17d714416686c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604468, encodeId=606e160446802, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202333, encodeId=0323120233314, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Sun Mar 13 22:12:02 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202151, encodeId=866d120215140, content=要大家共同努力,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Mar 13 06:35:05 CST 2022, time=2022-03-13, status=1, ipAttribution=)]
    2022-11-16 yaanren
  2. [GetPortalCommentsPageByObjectIdResponse(id=1648816, encodeId=a1231648816a5, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Wed Nov 16 08:59:29 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831490, encodeId=6e411831490c2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 12 09:59:29 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441668, encodeId=17d714416686c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604468, encodeId=606e160446802, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202333, encodeId=0323120233314, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Sun Mar 13 22:12:02 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202151, encodeId=866d120215140, content=要大家共同努力,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Mar 13 06:35:05 CST 2022, time=2022-03-13, status=1, ipAttribution=)]
    2022-12-12 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1648816, encodeId=a1231648816a5, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Wed Nov 16 08:59:29 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831490, encodeId=6e411831490c2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 12 09:59:29 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441668, encodeId=17d714416686c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604468, encodeId=606e160446802, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202333, encodeId=0323120233314, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Sun Mar 13 22:12:02 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202151, encodeId=866d120215140, content=要大家共同努力,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Mar 13 06:35:05 CST 2022, time=2022-03-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1648816, encodeId=a1231648816a5, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Wed Nov 16 08:59:29 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831490, encodeId=6e411831490c2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 12 09:59:29 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441668, encodeId=17d714416686c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604468, encodeId=606e160446802, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202333, encodeId=0323120233314, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Sun Mar 13 22:12:02 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202151, encodeId=866d120215140, content=要大家共同努力,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Mar 13 06:35:05 CST 2022, time=2022-03-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1648816, encodeId=a1231648816a5, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Wed Nov 16 08:59:29 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831490, encodeId=6e411831490c2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 12 09:59:29 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441668, encodeId=17d714416686c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604468, encodeId=606e160446802, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202333, encodeId=0323120233314, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Sun Mar 13 22:12:02 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202151, encodeId=866d120215140, content=要大家共同努力,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Mar 13 06:35:05 CST 2022, time=2022-03-13, status=1, ipAttribution=)]
    2022-03-13 萌宝嘟嘟

    好东西,谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1648816, encodeId=a1231648816a5, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Wed Nov 16 08:59:29 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831490, encodeId=6e411831490c2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Dec 12 09:59:29 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441668, encodeId=17d714416686c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604468, encodeId=606e160446802, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Mon Mar 14 06:59:29 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202333, encodeId=0323120233314, content=好东西,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0be2111725, createdName=萌宝嘟嘟, createdTime=Sun Mar 13 22:12:02 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202151, encodeId=866d120215140, content=要大家共同努力,造福人类, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Sun Mar 13 06:35:05 CST 2022, time=2022-03-13, status=1, ipAttribution=)]
    2022-03-13 未来将来

    要大家共同努力,造福人类

    0

相关资讯

超20万人研究:用抗生素一时爽,糖尿病风险蹭蹭涨?

Scientifc Reports:在韩国进行的具有全国代表性的回顾性队列研究中,抗生素使用与糖尿病发病率之间的关联

Clin Trans Gastroenterology:抗生素治疗和早发性结直肠癌的风险之间的关系

有传言说:“人用多了抗生素,抵抗力就会下降,甚至会引发癌症……”事实究竟如何呢?抗生素真的有这么可怕吗?

轻松分辨让人头痛的两种肺CT表现!

患者青年男性,咳嗽、低热2周,余无不适,外院给予头孢类抗生素治疗无效。查体:无异常。血常规正常。

中国侵袭性真菌感染临床实践能力提升项目公示

中国侵袭性真菌感染临床实践能力提升项目公示

IBD: 生命早期抗生素暴露和克罗恩病发病风险的相关性分析

宿主和肠道菌群在长期的进化过程中相互作用,共同调节肠道内环境稳态,对这一“共生-互益”的复杂机制的探索将对研究因肠道菌群异常而引起的疾病的发病机制具有重要意义。

拓展阅读

光活性“纳米抗菌剂”如何攻克细菌感染难题——《AFM》最新综述解析

该综述系统阐述了细菌耐药性基本理论和光敏纳米材料抗菌机制,深入解析了光活性抗菌纳米材料的优化设计和性能调控策略。

Sci Rep:手机新用途---检测细菌耐药性?

耐药细菌严重威胁着全球公共卫生,造成了越来越多的高死亡率疾病,如肺炎、腹泻和败血症等。对抗细菌耐药性的挑战之一是部分偏远地区由于缺乏设备和技术人员而无法检测细菌药物敏感性。为了解决这个问题,一个来自UCLA的团队开发了一种便宜而简便、可以自动检测细菌药物敏感性的手机附件,这项研究成果最近发表在《科学 报告》杂志上。 “考虑到耐药菌导致许多一线抗生素失效,从而严重威胁全球公共卫生,这项技术是

面对日益严峻的细菌耐药性形势 我们该如何应对?

近些年来,细菌感染引发的耐药细菌性疾病不断发生,抗生素耐药性的现象已经频频出现,面对很多感染性疾病我们束手无策,而且患者也被迫在医院多呆一些时间进行治疗,预计截止到2050年,抗生素耐药性每年会引发一千万人死亡,而且还会引发全球GDP发生100万亿的损失。 近日有研究者报道,超级细菌在污水中不断进化,很有可能将将危及人们的饮食安全;同时来自南佛罗里达大学的研究者通过研究发现,耐药性细

中国人体内发现无敌细菌无视抗生素?作者辟谣

中国人体内发现对抗生素耐药性强“超级细菌”基因?近日,这样一种说法迅速传遍网络,难道“后抗生素”时代真的来了?这种“超级细菌”真的存在?文章的源头是一篇学术文章。11月18日,国际最专业、权威的医学杂志《柳叶刀》(The Lancet)的子刊《柳叶刀·传染病》发布了一则最新研究报告。研究发现,在中国人体内,发现了应对多黏菌素抗生素的MCR -1基因。研究结果出炉后,有舆论称,MCR- 1基因的出现

世卫组织:全球应对“超级细菌”刻不容缓

刘慧 绘 长期以来,由于滥用抗生素或使用假抗生素导致细菌耐药性增强,产生所谓的“超级细菌”,已成为全球医疗卫生领域的一项难题。世界卫生组织助理总干事福田敬二不久前警告称,“‘超级细菌’对现代医学构成严峻考验,人类正进入‘后抗生素时代’,普通病菌感染再度成为致命因素。” 有评论称,“超级细菌”已经把人类逼到了近乎“无药可用”的境地,但也有乐观估计认为,在与“超级细菌”的战

Baidu
map
Baidu
map
Baidu
map